|
|
|
Gain Therapeutics inc (NASDAQ: GANX) |
|
Gain Therapeutics inc
Officers & Directors
Gianluca Fuggetta Finance Vice President - (Principal Financial Officer and Principal Accounting Officer) Dated; Khalid Islam Chairman of the Board of Directors Dated; Claude Nicaise Director Dated; Eric I. Richman Director Dated; Hans Peter Hasler Director Dated; Gwen Melincoff Director Dated; Matthias Alder Chief Executive Officer and Director - (Principal Executive Officer) Dated; Jeffrey Riley Director Dated; Dov Goldstein Director Dated; Matthias Alder Chief Executive Officer - (Principal Executive Officer) Date ,
Gain Therapeutics inc currently has 21 employees.
News about Gain Therapeutics inc Key Personnel |
Gain Therapeutics Inc. an innovative biotechnology firm focused on developing therapies for neurodegenerative diseases, has announced the appointment of Gene Mack as its new Chief Executive Officer (CEO) and Director. Mack has been with the company since April 2024, serving as Chief Financial Officer (CFO) before stepping in as the interim CEO in June 2024. His extensive experience in financial management and leadership positions him well to guide Gain Therapeutics through its current trials and tribulations.Mack s leadership comes at a critical time for Gain Therapeutics, which recorded a cumulative net loss of $21 million for the 12 months ending in the third quarter of 2024. This substantial loss has resu...
|
Gain Therapeutics Bolsters Management Team with Appointment of Chief Medical Officer, Dr. Jonas Hannestad
BETHESDA, Md., April 01, 2024 - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company specializing in the development of next-generation allosteric small molecule therapies, is pleased to announce the appointment of Dr. Jonas Hannestad, M.D., Ph.D., as its Chief Medical Officer. Dr. Hannestad assumed his new role on March 25, 2024, and his addition to the team is expected to provide valuable expertise and leadership as Gain Therapeutics continues its pioneering work in the field of biotechnology.
Recently, Gain Therapeutics Inc shares have experienced a slight decline and...
|
Gain Therapeutics, a renowned biotechnology company pioneering the breakthrough discovery and development of allosteric small molecule therapies, has recently provided an operational update through a letter addressed to shareholders from its President and Chief Executive Officer, Matthias Alder. The letter sheds light on the company s progress, achievements, and future prospects. Despite recording a net loss of $22 million in the previous year, Gain Therapeutics remains optimistic and committed to delivering innovative medical advancements in the field of healthcare.
In his letter, Matthias Alder acknowledges the shareholders continued support and expresses his confidence in the company s...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
